Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats
In the present study, the effects of intra-locus coeruleus injection of a dopamine D1 receptor agonist (SKF38393) on naloxone-induced withdrawal signs of morphine-dependent rats were examined. Twenty different withdrawal signs were assessed. The total withdrawal score was calculated and used as an i...
Gespeichert in:
| Veröffentlicht in: | Neuroreport 2005-10, Vol.16 (15), p.1683-1686 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1686 |
|---|---|
| container_issue | 15 |
| container_start_page | 1683 |
| container_title | Neuroreport |
| container_volume | 16 |
| creator | Dizgah, Iraj Mirzaii Karimian, Seyed Morteza Zarrindast, Mohammad Reza Sohanaki, Hamid |
| description | In the present study, the effects of intra-locus coeruleus injection of a dopamine D1 receptor agonist (SKF38393) on naloxone-induced withdrawal signs of morphine-dependent rats were examined. Twenty different withdrawal signs were assessed. The total withdrawal score was calculated and used as an index of withdrawal intensity for comparison. The D1 agonist and antagonist were injected 15 and 30 min prior to expression of naloxone-induced withdrawal signs, respectively. SKF38393 (2 and 4 μg/site) decreased while SCH23390 (a D1 antagonist) had no effect on the total withdrawal score. On the other hand, SCH23390 (25 ng/site) reversed the SKF38393 effect. It may be concluded that activation of dopamine D1 receptors in the locus coeruleus attenuates naloxone-induced withdrawal. |
| doi_str_mv | 10.1097/01.wnr.0000180142.91644.65 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20511563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20511563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3634-f22f30f7190a7acfa5623dd3efc9d131d8b2d6f1dfba952c32cf42b1d1cde5633</originalsourceid><addsrcrecordid>eNpFkE1v1DAQhi0EokvhLyALCW4Jnvhrza1qoUWqxAUkbsbxRxPIxovtKOq_xyUr7VxmZD3vjPUg9A5IC0TJjwTadU4tqQV7AqxrFQjGWsGfoR0wSRvO9z-fox1RXDVMCX6BXuX8u_KqJl6iCxCwV0zKHfp1VYqfF1PGOOMY8CGm4zDOHq9jGVwyq5lwHh_mjPtHbPAN4OStP5aYsHmI85gLHmdcBo-naJeMbfRpmXyd6rJkSn6NXgQzZf_m1C_Rjy-fv1_fNfffbr9eX903lgrKmtB1gZIgQREjjQ2Gi446R32wygEFt-87JwK40BvFO0s7G1jXgwPrPBeUXqIP295jin8Xn4s-jNn6aTKzj0vWHeEAG_hpA22KOScf9DGNB5MeNRD95FcT0NWvPvvV__1qwWv47enK0h-8O0dPQivw_gSYbM0UkpntmM-cBEm5hMqxjVvjVHzKf6Zl9UkP3kxl2E5LLpqO1G_XkTRPL4z-A9mIlZ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20511563</pqid></control><display><type>article</type><title>Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Dizgah, Iraj Mirzaii ; Karimian, Seyed Morteza ; Zarrindast, Mohammad Reza ; Sohanaki, Hamid</creator><creatorcontrib>Dizgah, Iraj Mirzaii ; Karimian, Seyed Morteza ; Zarrindast, Mohammad Reza ; Sohanaki, Hamid</creatorcontrib><description>In the present study, the effects of intra-locus coeruleus injection of a dopamine D1 receptor agonist (SKF38393) on naloxone-induced withdrawal signs of morphine-dependent rats were examined. Twenty different withdrawal signs were assessed. The total withdrawal score was calculated and used as an index of withdrawal intensity for comparison. The D1 agonist and antagonist were injected 15 and 30 min prior to expression of naloxone-induced withdrawal signs, respectively. SKF38393 (2 and 4 μg/site) decreased while SCH23390 (a D1 antagonist) had no effect on the total withdrawal score. On the other hand, SCH23390 (25 ng/site) reversed the SKF38393 effect. It may be concluded that activation of dopamine D1 receptors in the locus coeruleus attenuates naloxone-induced withdrawal.</description><identifier>ISSN: 0959-4965</identifier><identifier>EISSN: 1473-558X</identifier><identifier>DOI: 10.1097/01.wnr.0000180142.91644.65</identifier><identifier>PMID: 16189477</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins, Inc</publisher><subject><![CDATA[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - administration & dosage ; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - antagonists & inhibitors ; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - therapeutic use ; Animals ; Behavior, Animal - drug effects ; Benzazepines - administration & dosage ; Benzazepines - pharmacology ; Biological and medical sciences ; Dopamine Agonists - administration & dosage ; Dopamine Agonists - therapeutic use ; Drug addictions ; Injections ; Locus Coeruleus - physiology ; Male ; Medical sciences ; Morphine Dependence ; Naloxone - administration & dosage ; Naloxone - pharmacology ; Narcotic Antagonists - administration & dosage ; Narcotic Antagonists - pharmacology ; Rats ; Rats, Wistar ; Receptors, Dopamine D1 - agonists ; Receptors, Dopamine D1 - antagonists & inhibitors ; Substance Withdrawal Syndrome - drug therapy ; Toxicology]]></subject><ispartof>Neuroreport, 2005-10, Vol.16 (15), p.1683-1686</ispartof><rights>2005 Lippincott Williams & Wilkins, Inc.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3634-f22f30f7190a7acfa5623dd3efc9d131d8b2d6f1dfba952c32cf42b1d1cde5633</citedby><cites>FETCH-LOGICAL-c3634-f22f30f7190a7acfa5623dd3efc9d131d8b2d6f1dfba952c32cf42b1d1cde5633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17173571$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16189477$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dizgah, Iraj Mirzaii</creatorcontrib><creatorcontrib>Karimian, Seyed Morteza</creatorcontrib><creatorcontrib>Zarrindast, Mohammad Reza</creatorcontrib><creatorcontrib>Sohanaki, Hamid</creatorcontrib><title>Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats</title><title>Neuroreport</title><addtitle>Neuroreport</addtitle><description>In the present study, the effects of intra-locus coeruleus injection of a dopamine D1 receptor agonist (SKF38393) on naloxone-induced withdrawal signs of morphine-dependent rats were examined. Twenty different withdrawal signs were assessed. The total withdrawal score was calculated and used as an index of withdrawal intensity for comparison. The D1 agonist and antagonist were injected 15 and 30 min prior to expression of naloxone-induced withdrawal signs, respectively. SKF38393 (2 and 4 μg/site) decreased while SCH23390 (a D1 antagonist) had no effect on the total withdrawal score. On the other hand, SCH23390 (25 ng/site) reversed the SKF38393 effect. It may be concluded that activation of dopamine D1 receptors in the locus coeruleus attenuates naloxone-induced withdrawal.</description><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - administration & dosage</subject><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - antagonists & inhibitors</subject><subject>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - therapeutic use</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Benzazepines - administration & dosage</subject><subject>Benzazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Dopamine Agonists - administration & dosage</subject><subject>Dopamine Agonists - therapeutic use</subject><subject>Drug addictions</subject><subject>Injections</subject><subject>Locus Coeruleus - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Morphine Dependence</subject><subject>Naloxone - administration & dosage</subject><subject>Naloxone - pharmacology</subject><subject>Narcotic Antagonists - administration & dosage</subject><subject>Narcotic Antagonists - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors, Dopamine D1 - agonists</subject><subject>Receptors, Dopamine D1 - antagonists & inhibitors</subject><subject>Substance Withdrawal Syndrome - drug therapy</subject><subject>Toxicology</subject><issn>0959-4965</issn><issn>1473-558X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1v1DAQhi0EokvhLyALCW4Jnvhrza1qoUWqxAUkbsbxRxPIxovtKOq_xyUr7VxmZD3vjPUg9A5IC0TJjwTadU4tqQV7AqxrFQjGWsGfoR0wSRvO9z-fox1RXDVMCX6BXuX8u_KqJl6iCxCwV0zKHfp1VYqfF1PGOOMY8CGm4zDOHq9jGVwyq5lwHh_mjPtHbPAN4OStP5aYsHmI85gLHmdcBo-naJeMbfRpmXyd6rJkSn6NXgQzZf_m1C_Rjy-fv1_fNfffbr9eX903lgrKmtB1gZIgQREjjQ2Gi446R32wygEFt-87JwK40BvFO0s7G1jXgwPrPBeUXqIP295jin8Xn4s-jNn6aTKzj0vWHeEAG_hpA22KOScf9DGNB5MeNRD95FcT0NWvPvvV__1qwWv47enK0h-8O0dPQivw_gSYbM0UkpntmM-cBEm5hMqxjVvjVHzKf6Zl9UkP3kxl2E5LLpqO1G_XkTRPL4z-A9mIlZ4</recordid><startdate>20051017</startdate><enddate>20051017</enddate><creator>Dizgah, Iraj Mirzaii</creator><creator>Karimian, Seyed Morteza</creator><creator>Zarrindast, Mohammad Reza</creator><creator>Sohanaki, Hamid</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott Williams and Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20051017</creationdate><title>Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats</title><author>Dizgah, Iraj Mirzaii ; Karimian, Seyed Morteza ; Zarrindast, Mohammad Reza ; Sohanaki, Hamid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3634-f22f30f7190a7acfa5623dd3efc9d131d8b2d6f1dfba952c32cf42b1d1cde5633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - administration & dosage</topic><topic>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - antagonists & inhibitors</topic><topic>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - therapeutic use</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Benzazepines - administration & dosage</topic><topic>Benzazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Dopamine Agonists - administration & dosage</topic><topic>Dopamine Agonists - therapeutic use</topic><topic>Drug addictions</topic><topic>Injections</topic><topic>Locus Coeruleus - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Morphine Dependence</topic><topic>Naloxone - administration & dosage</topic><topic>Naloxone - pharmacology</topic><topic>Narcotic Antagonists - administration & dosage</topic><topic>Narcotic Antagonists - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors, Dopamine D1 - agonists</topic><topic>Receptors, Dopamine D1 - antagonists & inhibitors</topic><topic>Substance Withdrawal Syndrome - drug therapy</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dizgah, Iraj Mirzaii</creatorcontrib><creatorcontrib>Karimian, Seyed Morteza</creatorcontrib><creatorcontrib>Zarrindast, Mohammad Reza</creatorcontrib><creatorcontrib>Sohanaki, Hamid</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Neuroreport</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dizgah, Iraj Mirzaii</au><au>Karimian, Seyed Morteza</au><au>Zarrindast, Mohammad Reza</au><au>Sohanaki, Hamid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats</atitle><jtitle>Neuroreport</jtitle><addtitle>Neuroreport</addtitle><date>2005-10-17</date><risdate>2005</risdate><volume>16</volume><issue>15</issue><spage>1683</spage><epage>1686</epage><pages>1683-1686</pages><issn>0959-4965</issn><eissn>1473-558X</eissn><abstract>In the present study, the effects of intra-locus coeruleus injection of a dopamine D1 receptor agonist (SKF38393) on naloxone-induced withdrawal signs of morphine-dependent rats were examined. Twenty different withdrawal signs were assessed. The total withdrawal score was calculated and used as an index of withdrawal intensity for comparison. The D1 agonist and antagonist were injected 15 and 30 min prior to expression of naloxone-induced withdrawal signs, respectively. SKF38393 (2 and 4 μg/site) decreased while SCH23390 (a D1 antagonist) had no effect on the total withdrawal score. On the other hand, SCH23390 (25 ng/site) reversed the SKF38393 effect. It may be concluded that activation of dopamine D1 receptors in the locus coeruleus attenuates naloxone-induced withdrawal.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>16189477</pmid><doi>10.1097/01.wnr.0000180142.91644.65</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-4965 |
| ispartof | Neuroreport, 2005-10, Vol.16 (15), p.1683-1686 |
| issn | 0959-4965 1473-558X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20511563 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - administration & dosage 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - antagonists & inhibitors 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - therapeutic use Animals Behavior, Animal - drug effects Benzazepines - administration & dosage Benzazepines - pharmacology Biological and medical sciences Dopamine Agonists - administration & dosage Dopamine Agonists - therapeutic use Drug addictions Injections Locus Coeruleus - physiology Male Medical sciences Morphine Dependence Naloxone - administration & dosage Naloxone - pharmacology Narcotic Antagonists - administration & dosage Narcotic Antagonists - pharmacology Rats Rats, Wistar Receptors, Dopamine D1 - agonists Receptors, Dopamine D1 - antagonists & inhibitors Substance Withdrawal Syndrome - drug therapy Toxicology |
| title | Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T05%3A13%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Attenuation%20of%20morphine%20withdrawal%20signs%20by%20a%20D1%20receptor%20agonist%20in%20the%20locus%20coeruleus%20of%20rats&rft.jtitle=Neuroreport&rft.au=Dizgah,%20Iraj%20Mirzaii&rft.date=2005-10-17&rft.volume=16&rft.issue=15&rft.spage=1683&rft.epage=1686&rft.pages=1683-1686&rft.issn=0959-4965&rft.eissn=1473-558X&rft_id=info:doi/10.1097/01.wnr.0000180142.91644.65&rft_dat=%3Cproquest_cross%3E20511563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20511563&rft_id=info:pmid/16189477&rfr_iscdi=true |